{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T12:46:20Z","timestamp":1792413980867,"version":"4.4.0"},"reference-count":104,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:00:00Z","timestamp":1768348800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["SCR_022613"],"award-info":[{"award-number":["SCR_022613"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000937","name":"M J Murdock Charitable Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000937","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["P30 GM124169"],"award-info":[{"award-number":["P30 GM124169"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA285227"],"award-info":[{"award-number":["R01CA285227"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA015704"],"award-info":[{"award-number":["P30 CA015704"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000015","name":"US Department of Energy","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000015","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000011","name":"Howard Hughes Medical Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000011","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart Lung and Blood Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01AI147846"],"award-info":[{"award-number":["R01AI147846"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006132","name":"Office of Science","doi-asserted-by":"publisher","award":["DE-AC02-05CH11231"],"award-info":[{"award-number":["DE-AC02-05CH11231"]}],"id":[{"id":"10.13039\/100006132","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000052","name":"National Institutes of Health Office of the Director","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000052","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports Medicine"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.xcrm.2026.102618","type":"journal-article","created":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T16:07:55Z","timestamp":1771344475000},"page":"102618","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Transgenic mouse-derived human monoclonal antibodies targeting EBV gp350 and gp42 provide basis for therapeutic development"],"prefix":"10.1016","volume":"7","author":[{"given":"Crystal B.","family":"Chhan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amelia R.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Hsin","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas T.","family":"Aldridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gargi","family":"Kher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel C.","family":"Scharffenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha R.","family":"Hardy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman","family":"Iureniev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia V.","family":"Giltiay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina R.","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Radtke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Peter","family":"Kiem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Pancera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1841-6859","authenticated-orcid":false,"given":"Andrew T.","family":"McGuire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xcrm.2026.102618_bib1","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1056\/NEJM200008173430707","article-title":"Epstein-Barr virus infection","volume":"343","author":"Cohen","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2026.102618_bib2","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1073\/pnas.59.1.94","article-title":"Relation of Burkitt\u2019s tumor-associated herpes-ytpe virus to infectious mononucleosis","volume":"59","author":"Henle","year":"1968","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.xcrm.2026.102618_bib3","first-page":"211","article-title":"Infectious Mononucleosis","volume":"390","author":"Dunmire","year":"2015","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"10.1016\/j.xcrm.2026.102618_bib4","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1002\/ana.21978","article-title":"Primary infection with the Epstein-Barr virus and risk of multiple sclerosis","volume":"67","author":"Levin","year":"2010","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.xcrm.2026.102618_bib5","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0012496","article-title":"An updated meta-analysis of risk of multiple sclerosis following infectious mononucleosis","volume":"5","author":"Handel","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.xcrm.2026.102618_bib6","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/ana.20820","article-title":"Infectious mononucleosis and risk for multiple sclerosis: a meta-analysis","volume":"59","author":"Thacker","year":"2006","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.xcrm.2026.102618_bib7","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1177\/1352458511408991","article-title":"Anti-Epstein-Barr virus antibodies as serological markers of multiple sclerosis: a prospective study among United States military personnel","volume":"17","author":"Munger","year":"2011","journal-title":"Mult. Scler."},{"key":"10.1016\/j.xcrm.2026.102618_bib8","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1177\/1352458508100037","article-title":"Effects of infectious mononucleosis and HLA-DRB1\u221715 in multiple sclerosis","volume":"15","author":"Nielsen","year":"2009","journal-title":"Mult. Scler."},{"key":"10.1016\/j.xcrm.2026.102618_bib9","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s11481-010-9201-3","article-title":"Epstein-barr virus infection and multiple sclerosis: a review","volume":"5","author":"Ascherio","year":"2010","journal-title":"J. Neuroimmune Pharmacol."},{"key":"10.1016\/j.xcrm.2026.102618_bib10","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1126\/science.abj8222","article-title":"Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis","volume":"375","author":"Bjornevik","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.xcrm.2026.102618_bib11","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/s41584-024-01167-9","article-title":"Epstein-Barr virus as a potentiator of autoimmune diseases","volume":"20","author":"Robinson","year":"2024","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.xcrm.2026.102618_bib12","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.jbspin.2017.04.011","article-title":"Epstein-Barr virus and rheumatoid arthritis","volume":"85","author":"Balandraud","year":"2018","journal-title":"Jt. Bone Spine"},{"key":"10.1016\/j.xcrm.2026.102618_bib13","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1002\/art.41994","article-title":"Antibody Responses to Epstein-Barr Virus in the Preclinical Period of Rheumatoid Arthritis Suggest the Presence of Increased Viral Reactivation Cycles","volume":"74","author":"Fechtner","year":"2022","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.xcrm.2026.102618_bib14","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.cell.2022.01.014","article-title":"Multiple early factors anticipate post-acute COVID-19 sequelae","volume":"185","author":"Su","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2026.102618_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.virusres.2023.199157","article-title":"Incidence of Epstein-Barr virus reactivation is elevated in COVID-19 patients","volume":"334","author":"Bernal","year":"2023","journal-title":"Virus Res."},{"key":"10.1016\/j.xcrm.2026.102618_bib16","article-title":"Positive Epstein-Barr virus detection in coronavirus disease 2019 (COVID-19) patients","volume":"11","author":"Chen","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.xcrm.2026.102618_bib17","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s00432-021-03824-y","article-title":"Estimating the global burden of Epstein-Barr virus-related cancers","volume":"148","author":"Wong","year":"2022","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102618_bib18","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-037505","article-title":"Global and regional incidence, mortality and disability-adjusted life-years for Epstein-Barr virus-attributable malignancies, 1990\u20132017","volume":"10","author":"Khan","year":"2020","journal-title":"BMJ Open"},{"key":"10.1016\/j.xcrm.2026.102618_bib19","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1146\/annurev-immunol-032414-112326","article-title":"The Immunology of Epstein-Barr Virus\u2013Induced Disease","volume":"33","author":"Taylor","year":"2015","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.xcrm.2026.102618_bib20","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.867918","article-title":"Four Decades of Prophylactic EBV Vaccine Research: A Systematic Review and Historical Perspective","volume":"13","author":"Escalante","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.xcrm.2026.102618_bib21","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.3390\/v14112372","article-title":"How EBV Infects: The Tropism and Underlying Molecular Mechanism for Viral Infection","volume":"14","author":"Bu","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.xcrm.2026.102618_bib22","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/s41579-020-00448-w","article-title":"The structural basis of herpesvirus entry","volume":"19","author":"Connolly","year":"2021","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.xcrm.2026.102618_bib23","doi-asserted-by":"crossref","DOI":"10.3390\/v14020296","article-title":"Well Put Together-A Guide to Accessorizing with the Herpesvirus gH\/gL Complexes","volume":"14","author":"Gonzalez-Del Pino","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.xcrm.2026.102618_bib24","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/s41586-025-09166-w","article-title":"R9AP is a common receptor for EBV infection in epithelial cells and B cells","volume":"644","author":"Li","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2026.102618_bib25","doi-asserted-by":"crossref","first-page":"4510","DOI":"10.1073\/pnas.81.14.4510","article-title":"Epstein-Barr virus receptor of human B lymphocytes is the C3d receptor CR2","volume":"81","author":"Fingeroth","year":"1984","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.xcrm.2026.102618_bib26","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/0092-8674(87)90216-9","article-title":"Epstein-barr virus gp350\/220 binding to the B lymphocyte C3d receptor mediates adsorption, capping, and endocytosis","volume":"50","author":"Tanner","year":"1987","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2026.102618_bib27","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.celrep.2013.01.023","article-title":"Human Complement Receptor Type 1\/CD35 Is an Epstein-Barr Virus Receptor","volume":"3","author":"Ogembo","year":"2013","journal-title":"Cell Rep."},{"key":"10.1016\/j.xcrm.2026.102618_bib28","doi-asserted-by":"crossref","first-page":"9444","DOI":"10.1128\/JVI.00572-06","article-title":"Soluble Epstein-Barr virus glycoproteins gH, gL, and gp42 form a 1:1:1 stable complex that acts like soluble gp42 in B-cell fusion but not in epithelial cell fusion","volume":"80","author":"Kirschner","year":"2006","journal-title":"J. Virol."},{"key":"10.1016\/j.xcrm.2026.102618_bib29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1004309","article-title":"Assembly and Architecture of the EBV B Cell Entry Triggering Complex","volume":"10","author":"Sathiyamoorthy","year":"2014","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.xcrm.2026.102618_bib30","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1128\/JVI.74.5.2451-2454.2000","article-title":"Epstein-Barr virus entry utilizing HLA-DP or HLA-DQ as a coreceptor","volume":"74","author":"Haan","year":"2000","journal-title":"J. Virol."},{"key":"10.1016\/j.xcrm.2026.102618_bib31","doi-asserted-by":"crossref","first-page":"5557","DOI":"10.1128\/jvi.70.8.5557-5563.1996","article-title":"The extracellular domain of the Epstein-Barr virus BZLF2 protein binds the HLA-DR beta chain and inhibits antigen presentation","volume":"70","author":"Spriggs","year":"1996","journal-title":"J. Virol."},{"key":"10.1016\/j.xcrm.2026.102618_bib32","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms13557","article-title":"Structural basis for Epstein\u2013Barr virus host cell tropism mediated by gp42 and gHgL entry glycoproteins","volume":"7","author":"Sathiyamoorthy","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2026.102618_bib33","article-title":"Potent human monoclonal antibodies targeting Epstein-Barr virus gp42 reveal vulnerable sites for virus infection","volume":"5","author":"Zhao","year":"2024","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.xcrm.2026.102618_bib34","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.immuni.2024.02.008","article-title":"Epstein-Barr virus gp42 antibodies reveal sites of vulnerability for receptor binding and fusion to B cells","volume":"57","author":"Bu","year":"2024","journal-title":"Immunity"},{"key":"10.1016\/j.xcrm.2026.102618_bib35","doi-asserted-by":"crossref","first-page":"5946","DOI":"10.1128\/JVI.78.11.5946-5956.2004","article-title":"Mutational analyses of Epstein-Barr virus glycoprotein 42 reveal functional domains not involved in receptor binding but required for membrane fusion","volume":"78","author":"Silva","year":"2004","journal-title":"J. Virol."},{"key":"10.1016\/j.xcrm.2026.102618_bib36","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.str.2008.12.010","article-title":"Structure of Epstein-Barr Virus Glycoprotein 42 Suggests a Mechanism for Triggering Receptor-Activated Virus Entry","volume":"17","author":"Kirschner","year":"2009","journal-title":"Structure"},{"key":"10.1016\/j.xcrm.2026.102618_bib37","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1097-2765(02)00465-3","article-title":"Structure of the Epstein-Barr Virus gp42 Protein Bound to the MHC Class II Receptor HLA-DR1","volume":"9","author":"Mullen","year":"2002","journal-title":"Mol. Cell"},{"key":"10.1016\/j.xcrm.2026.102618_bib38","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1146\/annurev.immunol.25.022106.141553","article-title":"Cellular Responses to Viral Infection in Humans: Lessons from Epstein-Barr Virus","volume":"25","author":"Hislop","year":"2007","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.xcrm.2026.102618_bib39","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.it.2014.01.003","article-title":"Cellular immune controls over Epstein-Barr virus infection: new lessons from the clinic and the laboratory","volume":"35","author":"Rickinson","year":"2014","journal-title":"Trends Immunol."},{"key":"10.1016\/j.xcrm.2026.102618_bib40","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.it.2008.01.006","article-title":"Epstein-Barr virus: a paradigm for persistent infection - for real and in virtual reality","volume":"29","author":"Thorley-Lawson","year":"2008","journal-title":"Trends Immunol."},{"key":"10.1016\/j.xcrm.2026.102618_bib41","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.canlet.2011.02.007","article-title":"HIV, EBV and KSHV: viral cooperation in the pathogenesis of human malignancies","volume":"305","author":"da Silva","year":"2011","journal-title":"Cancer Lett."},{"key":"10.1016\/j.xcrm.2026.102618_bib42","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0140-6736(07)61050-2","article-title":"Incidence of cancers in people with HIV\/AIDS compared with immunosuppressed transplant recipients: a meta-analysis","volume":"370","author":"Grulich","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.xcrm.2026.102618_bib43","doi-asserted-by":"crossref","DOI":"10.3390\/v16081294","article-title":"EBV Reactivation and Disease in Allogeneic Hematopoietic Stem Cell Transplant (HSCT) Recipients and Its Impact on HSCT Outcomes","volume":"16","author":"Law","year":"2024","journal-title":"Viruses"},{"key":"10.1016\/j.xcrm.2026.102618_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.semnephrol.2024.151503","article-title":"Post-Transplant Lymphoproliferative Disorders","volume":"44","author":"Dharnidharka","year":"2024","journal-title":"Semin. Nephrol."},{"key":"10.1016\/j.xcrm.2026.102618_bib45","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1034\/j.1399-3062.2001.003002070.x","article-title":"Identifying the patient at risk for post-transplant lymphoproliferative disorder","volume":"3","author":"Cockfield","year":"2001","journal-title":"Transpl. Infect. Dis."},{"key":"10.1016\/j.xcrm.2026.102618_bib46","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1093\/clinids\/20.5.1346","article-title":"Pretransplantation assessment of the risk of lymphoproliferative disorder","volume":"20","author":"Walker","year":"1995","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.xcrm.2026.102618_bib47","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1097\/TP.0b013e318269e64f","article-title":"The Seville expert workshop for progress in posttransplant lymphoproliferative disorders","volume":"94","author":"Glotz","year":"2012","journal-title":"Transplantation"},{"key":"10.1016\/j.xcrm.2026.102618_bib48","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1086\/505912","article-title":"A mouse monoclonal antibody against Epstein-Barr virus envelope glycoprotein 350 prevents infection both in vitro and in vivo","volume":"194","author":"Haque","year":"2006","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.xcrm.2026.102618_bib49","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.00075-22","article-title":"A Neutralizing Antibody Targeting gH Provides Potent Protection against EBV Challenge In Vivo","volume":"96","author":"Hong","year":"2022","journal-title":"J. Virol."},{"key":"10.1016\/j.xcrm.2026.102618_bib50","doi-asserted-by":"crossref","first-page":"6624","DOI":"10.1038\/s41467-021-26912-6","article-title":"A potent and protective human neutralizing antibody targeting a novel vulnerable site of Epstein-Barr virus","volume":"12","author":"Zhu","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2026.102618_bib51","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1016\/j.immuni.2022.10.003","article-title":"Epstein-Barr virus gH\/gL has multiple sites of vulnerability for virus neutralization and fusion inhibition","volume":"55","author":"Chen","year":"2022","journal-title":"Immunity"},{"key":"10.1016\/j.xcrm.2026.102618_bib52","article-title":"Protective anti-gB neutralizing antibodies targeting two vulnerable sites for EBV-cell membrane fusion","volume":"119","author":"Zhang","year":"2022","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.xcrm.2026.102618_bib53","article-title":"Non-overlapping epitopes on the gHgL-gp42 complex for the rational design of a triple-antibody cocktail against EBV infection","volume":"4","author":"Hong","year":"2023","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.xcrm.2026.102618_bib55","article-title":"Neutralizing Antibodies Protect against Oral Transmission of Lymphocryptovirus","volume":"1","author":"Singh","year":"2020","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.xcrm.2026.102618_bib54","article-title":"Neutralizing antibodies against Epstein-Barr virus infection of B cells can protect from oral viral challenge in the rhesus macaque animal model","volume":"2","author":"M\u00fche","year":"2021","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.xcrm.2026.102618_bib56","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.1073\/pnas.77.5.2979","article-title":"Monoclonal antibody against a 250,000-dalton glycoprotein of Epstein-Barr virus identifies a membrane antigen and a neutralizing antigen","volume":"77","author":"Hoffman","year":"1980","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.xcrm.2026.102618_bib57","doi-asserted-by":"crossref","DOI":"10.3390\/cancers10040112","article-title":"Construction and Characterization of a Humanized Anti-Epstein-Barr Virus gp350 Antibody with Neutralizing Activity in Cell Culture","volume":"10","author":"Tanner","year":"2018","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.xcrm.2026.102618_bib58","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.virol.2019.07.026","article-title":"Identification of multiple potent neutralizing and non-neutralizing antibodies against Epstein-Barr virus gp350 protein with potential for clinical application and as reagents for mapping immunodominant epitopes","volume":"536","author":"Mutsvunguma","year":"2019","journal-title":"Virology"},{"key":"10.1016\/j.xcrm.2026.102618_bib59","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.immuni.2018.03.026","article-title":"An antibody targeting the fusion machinery neutralizes dual-tropic infection and defines a site of vulnerability on Epstein-Barr virus","volume":"48","author":"Snijder","year":"2018","journal-title":"Immunity"},{"key":"10.1016\/j.xcrm.2026.102618_bib60","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.immuni.2025.01.010","article-title":"Structural basis for complement receptor engagement and virus neutralization through Epstein-Barr virus gp350","volume":"58","author":"Joyce","year":"2025","journal-title":"Immunity"},{"key":"10.1016\/j.xcrm.2026.102618_bib62","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/356347a0","article-title":"Epstein-Barr virus infection and replication in a human epithelial cell system","volume":"356","author":"Li","year":"1992","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2026.102618_bib63","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.celrep.2013.09.012","article-title":"Spontaneous lytic replication and epitheliotropism define an Epstein-Barr virus strain found in carcinomas","volume":"5","author":"Tsai","year":"2013","journal-title":"Cell Rep."},{"key":"10.1016\/j.xcrm.2026.102618_bib64","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1093\/infdis\/jiaa654","article-title":"Maternal Epstein-Barr Virus-Specific Antibodies and Risk of Infection in Ugandan Infants","volume":"223","author":"Minab","year":"2021","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.xcrm.2026.102618_bib65","doi-asserted-by":"crossref","first-page":"44266","DOI":"10.18632\/oncotarget.17863","article-title":"Leflunomide\/teriflunomide inhibit Epstein-Barr virus (EBV)-induced lymphoproliferative disease and lytic viral replication","volume":"8","author":"Bilger","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.xcrm.2026.102618_bib66","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01918-19","article-title":"Identification and Cloning of a New Western Epstein-Barr Virus Strain That Efficiently Replicates in Primary B Cells","volume":"94","author":"Delecluse","year":"2020","journal-title":"J. Virol."},{"key":"10.1016\/j.xcrm.2026.102618_bib67","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.omto.2020.08.005","article-title":"CAR-T Cells Targeting Epstein-Barr Virus gp350 Validated in a Humanized Mouse Model of EBV Infection and Lymphoproliferative Disease","volume":"18","author":"Slabik","year":"2020","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.xcrm.2026.102618_bib68","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.1128\/jvi.69.7.3987-3994.1995","article-title":"The Epstein-Barr virus (EBV) BZLF2 gene product associates with the gH and gL homologs of EBV and carries an epitope critical to infection of B cells but not of epithelial cells","volume":"69","author":"Li","year":"1995","journal-title":"J. Virol."},{"key":"10.1016\/j.xcrm.2026.102618_bib69","doi-asserted-by":"crossref","DOI":"10.1080\/22221751.2023.2245920","article-title":"Neutralizing antibodies against EBV gp42 show potent in vivo protection and define novel epitopes","volume":"12","author":"Wu","year":"2023","journal-title":"Emerg. Microbes Infect."},{"key":"10.1016\/j.xcrm.2026.102618_bib70","article-title":"Immunization with Epstein-Barr Virus Core Fusion Machinery Envelope Proteins Elicit High Titers of Neutralizing Activities and Protect Humanized Mice from Lethal Dose EBV Challenge","volume":"9","author":"Cui","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.xcrm.2026.102618_bib71","article-title":"Immunization with a self-assembling nanoparticle vaccine displaying EBV gH\/gL protects humanized mice against lethal viral challenge","volume":"3","author":"Malhi","year":"2022","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.xcrm.2026.102618_bib72","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/s41541-024-00907-y","article-title":"A gH\/gL-encoding replicon vaccine elicits neutralizing antibodies that protect humanized mice against EBV challenge","volume":"9","author":"Edwards","year":"2024","journal-title":"npj Vaccines"},{"key":"10.1016\/j.xcrm.2026.102618_bib73","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1182\/bloodadvances.2023011371","article-title":"Choosing the right mouse model: comparison of humanized NSG and NBSGW mice for in vivo HSC gene therapy","volume":"8","author":"Choo","year":"2024","journal-title":"Blood Adv."},{"key":"10.1016\/j.xcrm.2026.102618_bib74","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1126\/science.1187659","article-title":"Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1","volume":"329","author":"Wu","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.xcrm.2026.102618_bib75","doi-asserted-by":"crossref","first-page":"7374","DOI":"10.1128\/jvi.68.11.7374-7385.1994","article-title":"Epstein-Barr virus latency in blood mononuclear cells: analysis of viral gene transcription during primary infection and in the carrier state","volume":"68","author":"Tierney","year":"1994","journal-title":"J. Virol."},{"key":"10.1016\/j.xcrm.2026.102618_bib76","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.cell.2015.07.043","article-title":"Rational Design of an Epstein-Barr Virus Vaccine Targeting the Receptor-Binding Site","volume":"162","author":"Kanekiyo","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2026.102618_bib77","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/j.immuni.2019.03.010","article-title":"Immunization with Components of the Viral Fusion Apparatus Elicits Antibodies That Neutralize Epstein-Barr Virus in B Cells and Epithelial Cells","volume":"50","author":"Bu","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.xcrm.2026.102618_bib78","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abf3685","article-title":"A bivalent Epstein-Barr virus vaccine induces neutralizing antibodies that block infection and confer immunity in humanized mice","volume":"14","author":"Wei","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.xcrm.2026.102618_bib79","doi-asserted-by":"crossref","first-page":"10142","DOI":"10.1128\/JVI.74.21.10142-10152.2000","article-title":"Infectious Epstein-Barr virus lacking major glycoprotein BLLF1 (gp350\/220) demonstrates the existence of additional viral ligands","volume":"74","author":"Janz","year":"2000","journal-title":"J. Virol."},{"key":"10.1016\/j.xcrm.2026.102618_bib80","doi-asserted-by":"crossref","first-page":"153","DOI":"10.3390\/pathogens2010153","article-title":"Humanized mouse models of epstein-barr virus infection and associated diseases","volume":"2","author":"Fujiwara","year":"2013","journal-title":"Pathogens"},{"key":"10.1016\/j.xcrm.2026.102618_bib81","doi-asserted-by":"crossref","DOI":"10.3390\/pathogens9020116","article-title":"Animal Models for Gammaherpesvirus Infections: Recent Development in the Analysis of Virus-Induced Pathogenesis","volume":"9","author":"Fujiwara","year":"2020","journal-title":"Pathogens"},{"key":"10.1016\/j.xcrm.2026.102618_bib82","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1111\/j.1600-0714.2008.00681.x","article-title":"Laser-capture microdissection of oropharyngeal epithelium indicates restriction of Epstein-Barr virus receptor\/CD21 mRNA to tonsil epithelial cells","volume":"37","author":"Jiang","year":"2008","journal-title":"J. Oral Pathol. Med."},{"key":"10.1016\/j.xcrm.2026.102618_bib83","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1011040","article-title":"New insight into Epstein-Barr virus infection using models of stratified epithelium","volume":"19","author":"Hayman","year":"2023","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.xcrm.2026.102618_bib84","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nm830","article-title":"Epstein-Barr virus infection of polarized tongue and nasopharyngeal epithelial cells","volume":"9","author":"Tugizov","year":"2003","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2026.102618_bib85","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1038\/s41422-020-00402-8","article-title":"Single-cell transcriptomic analysis defines the interplay between tumor cells, viral infection, and the microenvironment in nasopharyngeal carcinoma","volume":"30","author":"Jin","year":"2020","journal-title":"Cell Res."},{"key":"10.1016\/j.xcrm.2026.102618_bib86","article-title":"A large-scale population-based study reveals that gp42-IgG antibody is protective against EBV\u2013associated nasopharyngeal carcinoma","volume":"135","author":"Kong","year":"2024","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.xcrm.2026.102618_bib87","doi-asserted-by":"crossref","first-page":"8245","DOI":"10.1073\/pnas.95.14.8245","article-title":"Propagation and recovery of intact, infectious Epstein-Barr virus from prokaryotic to human cells","volume":"95","author":"Delecluse","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.xcrm.2026.102618_bib88","doi-asserted-by":"crossref","first-page":"6324","DOI":"10.1128\/JVI.74.14.6324-6332.2000","article-title":"Epstein-Barr virus gH is essential for penetration of B cells but also plays a role in attachment of virus to epithelial cells","volume":"74","author":"Molesworth","year":"2000","journal-title":"J. Virol."},{"key":"10.1016\/j.xcrm.2026.102618_bib89","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1128\/JCM.37.1.132-136.1999","article-title":"Quantitative analysis of Epstein-Barr virus load by using a real-time PCR assay","volume":"37","author":"Kimura","year":"1999","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.xcrm.2026.102618_bib90","doi-asserted-by":"crossref","first-page":"5222","DOI":"10.1128\/JVI.03614-14","article-title":"Genome diversity of Epstein-Barr virus from multiple tumor types and normal infection","volume":"89","author":"Palser","year":"2015","journal-title":"J. Virol."},{"key":"10.1016\/j.xcrm.2026.102618_bib91","doi-asserted-by":"crossref","first-page":"15036","DOI":"10.1073\/pnas.232381299","article-title":"Glycoprotein gp110 of Epstein-Barr virus determines viral tropism and efficiency of infection","volume":"99","author":"Neuhierl","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.xcrm.2026.102618_bib92","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jsb.2005.03.010","article-title":"Automated molecular microscopy: the new Leginon system","volume":"151","author":"Suloway","year":"2005","journal-title":"J. Struct. Biol."},{"key":"10.1016\/j.xcrm.2026.102618_bib93","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/nmeth.4169","article-title":"cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination","volume":"14","author":"Punjani","year":"2017","journal-title":"Nat. Methods"},{"key":"10.1016\/j.xcrm.2026.102618_bib94","doi-asserted-by":"crossref","DOI":"10.1002\/pro.4792","article-title":"UCSF ChimeraX: Tools for structure building and analysis","volume":"32","author":"Meng","year":"2023","journal-title":"Protein Sci."},{"key":"10.1016\/j.xcrm.2026.102618_bib95","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s41586-024-07487-w","article-title":"Accurate structure prediction of biomolecular interactions with AlphaFold 3","volume":"630","author":"Abramson","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2026.102618_bib96","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1107\/S0907444909047337","article-title":"XDS","volume":"66","author":"Kabsch","year":"2010","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"10.1016\/j.xcrm.2026.102618_bib97","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1107\/S2059798323003595","article-title":"The CCP4 suite: integrative software for macromolecular crystallography","volume":"79","author":"Agirre","year":"2023","journal-title":"Acta Crystallogr. D Struct. Biol."},{"key":"10.1016\/j.xcrm.2026.102618_bib98","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1107\/S0907444910007493","article-title":"Features and development of Coot","volume":"66","author":"Emsley","year":"2010","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"10.1016\/j.xcrm.2026.102618_bib99","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1107\/S2059798319011471","article-title":"Macromolecular structure determination using X-rays, neutrons and electrons: recent developments in Phenix","volume":"75","author":"Liebschner","year":"2019","journal-title":"Acta Crystallogr. D Struct. Biol."},{"key":"10.1016\/j.xcrm.2026.102618_bib100","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.jmb.2007.05.022","article-title":"Inference of macromolecular assemblies from crystalline state","volume":"372","author":"Krissinel","year":"2007","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.xcrm.2026.102618_bib101","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.stemcr.2014.12.005","article-title":"Nonirradiated NOD, B6.SCID Il2r\u03b3-\/- Kit(W41\/W41) (NBSGW) mice support multilineage engraftment of human hematopoietic cells","volume":"4","author":"McIntosh","year":"2015","journal-title":"Stem Cell Rep."},{"key":"10.1016\/j.xcrm.2026.102618_bib102","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0218717","article-title":"A simplified workflow for monoclonal antibody sequencing","volume":"14","author":"Meyer","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.xcrm.2026.102618_bib103","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.virol.2009.06.013","article-title":"Human antibody titers to Epstein-Barr Virus (EBV) gp350 correlate with neutralization of infectivity better than antibody titers to EBV gp42 using a rapid flow cytometry-based EBV neutralization assay","volume":"391","author":"Sashihara","year":"2009","journal-title":"Virology"},{"key":"10.1016\/j.xcrm.2026.102618_bib104","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1126\/science.1093933","article-title":"Development of a human adaptive immune system in cord blood cell-transplanted mice","volume":"304","author":"Traggiai","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.xcrm.2026.102618_bib105","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/978-1-4939-3606-9_22","article-title":"Generation of Humanized Mice for Analysis of Human Dendritic Cells","volume":"1423","author":"Saito","year":"2016","journal-title":"Methods Mol. Biol."}],"container-title":["Cell Reports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379126000352?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379126000352?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T13:21:19Z","timestamp":1775308879000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666379126000352"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":104,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S2666379126000352"],"URL":"https:\/\/doi.org\/10.1016\/j.xcrm.2026.102618","relation":{},"ISSN":["2666-3791"],"issn-type":[{"value":"2666-3791","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Transgenic mouse-derived human monoclonal antibodies targeting EBV gp350 and gp42 provide basis for therapeutic development","name":"articletitle","label":"Article Title"},{"value":"Cell Reports Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xcrm.2026.102618","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102618"}}